A Belgium based synthetic biology specialist company developing original genetic technologies using bacteriocins has appointed Aagami to support out-l...
Published : 25 Jun 2019
Read MoreAagami will support out-licensing in India and selective other regions for an Israel based BioPharma Company with ‘Novel Treatment for Non-Surgical ...
Published : 03 Jun 2019
Read MoreAagami CEO, Dinesh Jain, is participating in the 2019 BIO International Convention which will be held in Philadelphia (June 3-6, 2019). This Annu...
Published : 15 May 2019
Read MoreOur new client is focused on transforming Lab innovations of India into market commercialization. Aagami has been selected to take such off...
Published : 01 Apr 2019
Read MoreOur new Korean client has developed E. coli Monophosphoryl Lipid A, a novel adjuvant. This is directly produced in genetically engineered E. coli and ...
Published : 05 Mar 2019
Read MoreAagami will support development of a breakthrough life-saving drug to treat alcohol poisoning of a client from Israel. Along with our associates we sh...
Published : 28 Feb 2019
Read MoreIn keeping up with the annual tradition, Aagami is participating in JP Morgan Healthcare conference and BioTech Showcase January 2019. Both event...
Published : 02 Dec 2018
Read MoreAs part of its extensive networking and representation of Aagami clients Mr. Dinesh Jain, Founder CEO of Aagami, attended Bio-Europe 2018 - Copenhagen...
Published : 09 Nov 2018
Read MoreIn a yet another client win, Aagami received an assignment from an Innovative company who has developed an Abuse Deterrent and Life Saving Drug to add...
Published : 03 Aug 2018
Read MoreApart from promoting Aagami Inc, Dinesh Jain, the Founder CEO will be representing 2 clients at the The BIO International Convention 2018.The industry...
Published : 01 Jun 2018
Read More